Medical Device Sector Is Most Active in H1:17

The Medical Device sector has been humming. Granted, it comprises a huge range of things, from hip and knee joints to cardiovascular devices. Since 2016, 176 deals have been announced, and $102 billion has been committed based on 73 disclosed prices. Among the 176 deals, 14 target companies specialize in cardiovascular devices, 14 specialize in orthopedic and spine devices, 10 specialize in aesthetic devices each, and eight specialize in vascular devices, to name a few. The most recent deal, on July 10, was of a company that covered a very interesting niche of medical devices. ThermoGenesis Corp., a wholly-owned subsidiary of Cesca Therapeutics Inc., (NASDAQ: KOOL) acquired privately held... Read More »

Spending on Health Care Deals Popped in April

April deal volume disappointed, with 103 deals and a decrease of 29% compared with March 2017 (145 deals). On the spending side, April’s preliminary spending total increased 931% compared with the previous month’s $4.8 billion. Here’s the breakdown. April’s combined spending hit $49.9 billion, which was 15% higher than the total in April 2016. This month’s high was the result of a single large deal, the $24 billion spent by Becton, Dickinson and Company (NYSE: BDX) for C.R. Bard (NYSE: CBR), in the Medical Device sector. Also worth noting is the more than $9.0 billion spent by Hellman & Friedman to buy out the majority stake owned partner, The Carlyle Group (NYSE:... Read More »

Becton, Dickinson Leads the Medical Device Sector

The Medical Device sector isn’t seeing a flood of deals, but the dollars are adding up fast. In the first four months of 2017, dollars committed to deals in this sector have reached 60% of 2016’s total of $61.6 billion. With just 31 deals announced, deal volume stands at 27% of last year’s total of 112 transactions. Four deals have surpassed the $1 billion mark this year, and one currently accounts for 65% of this year’s $36.9 billion total. That deal, recently announced, is Becton, Dickinson and Company’s (NYSE: BDX) $24 billion purchase of C.R. Bard, Inc. (NYSE: BCR). In late April, Becton, Dickinson (BD) announced it would pay $317.00 per share for the New Jersey-based... Read More »